|By Marketwired .||
|February 28, 2014 01:50 PM EST||
LAGUNA HILLS, CA -- (Marketwired) -- 02/28/14 -- Itonis, Inc. (PINKSHEETS: ITNS) is pleased to announce that it has received and is currently evaluating samples of its Emesyl product from its manufacturer. Oasis Health Products, Inc. delivered two versions of the Emesyl anti-nausea formula which are currently being evaluating for tolerance.
"The two versions differ in terms of preservative," says Ernesto Barron, Itonis' recently appointed Chief Scientific Officer. "We are looking at using a class of preservative that will not only maintain product stability but also will serve to sooth the nasal passages."
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
Aug. 28, 2016 08:30 PM EDT Reads: 1,796
Aug. 28, 2016 08:15 PM EDT Reads: 1,924
Aug. 28, 2016 07:30 PM EDT Reads: 667
Aug. 28, 2016 06:30 PM EDT Reads: 1,598
Aug. 28, 2016 06:00 PM EDT Reads: 1,911
Aug. 28, 2016 05:30 PM EDT Reads: 720
Aug. 28, 2016 03:15 PM EDT Reads: 3,482
Aug. 28, 2016 03:00 PM EDT Reads: 736
Aug. 28, 2016 01:45 PM EDT Reads: 3,650
Aug. 28, 2016 01:00 PM EDT Reads: 2,415
Aug. 28, 2016 12:15 PM EDT Reads: 843
Aug. 28, 2016 11:45 AM EDT Reads: 679
Aug. 28, 2016 11:30 AM EDT Reads: 1,952
Aug. 28, 2016 11:00 AM EDT Reads: 696
Aug. 28, 2016 11:00 AM EDT Reads: 3,121